Biolase Stock Price To Earnings To Growth
| BIOLDelisted Stock | USD 0.05 0.02 27.46% |
BIOLASE fundamentals help investors to digest information that contributes to BIOLASE's financial success or failures. It also enables traders to predict the movement of BIOLASE Stock. The fundamental analysis module provides a way to measure BIOLASE's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BIOLASE stock.
BIOLASE |
BIOLASE Company Price To Earnings To Growth Analysis
BIOLASE's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Current BIOLASE Price To Earnings To Growth | (0.22) X |
Most of BIOLASE's fundamental indicators, such as Price To Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BIOLASE is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
CompetitionBased on the latest financial disclosure, BIOLASE has a Price To Earnings To Growth of -0.22 times. This is 130.99% lower than that of the Health Care Equipment & Supplies sector and 111.58% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 104.5% higher than that of the company.
BIOLASE Price To Earnings To Growth Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BIOLASE's direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BIOLASE could also be used in its relative valuation, which is a method of valuing BIOLASE by comparing valuation metrics of similar companies.BIOLASE is currently under evaluation in price to earnings to growth category among its peers.
BIOLASE Fundamentals
| Return On Equity | -5.05 | |||
| Return On Asset | -0.27 | |||
| Profit Margin | (0.44) % | |||
| Operating Margin | (0.45) % | |||
| Current Valuation | 13.65 M | |||
| Shares Outstanding | 33.4 M | |||
| Shares Owned By Insiders | 0.32 % | |||
| Shares Owned By Institutions | 8.97 % | |||
| Number Of Shares Shorted | 2.1 M | |||
| Price To Earning | (7.23) X | |||
| Price To Book | 0.77 X | |||
| Price To Sales | 0.1 X | |||
| Revenue | 49.16 M | |||
| Gross Profit | 16.53 M | |||
| EBITDA | (15.14 M) | |||
| Net Income | (20.63 M) | |||
| Cash And Equivalents | 9.96 M | |||
| Cash Per Share | 1.39 X | |||
| Total Debt | 17.91 M | |||
| Debt To Equity | 1.07 % | |||
| Current Ratio | 2.46 X | |||
| Book Value Per Share | (0.06) X | |||
| Cash Flow From Operations | (14.09 M) | |||
| Short Ratio | 1.09 X | |||
| Earnings Per Share | (11.97) X | |||
| Price To Earnings To Growth | (0.22) X | |||
| Target Price | 1.95 | |||
| Number Of Employees | 157 | |||
| Beta | 0.75 | |||
| Market Capitalization | 4.31 M | |||
| Total Asset | 35.1 M | |||
| Retained Earnings | (316.8 M) | |||
| Working Capital | 5.2 M | |||
| Current Asset | 34.8 M | |||
| Current Liabilities | 15.11 M | |||
| Net Asset | 35.1 M |
About BIOLASE Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BIOLASE's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BIOLASE using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BIOLASE based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Other Consideration for investing in BIOLASE Stock
If you are still planning to invest in BIOLASE check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BIOLASE's history and understand the potential risks before investing.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |